A Case of Non-Cirrhotic Portal Hypertension Associated With Chronic Didanosine Therapy

Matthew Stotts, MD,1 Phillip Chisholm, MD,2 Diana Nurutdinova, MD,3 and Haripriya Maddur, MD4

1Department of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO
2Department of Internal Medicine, Washington University, St. Louis, MO
3Department of Infectious Diseases, John Cochran Veterans Affairs Hospital, Washington University, St. Louis, MO
4Department of Gastroenterology and Hepatology, John Cochran Veterans Affairs Hospital, Washington University, St. Louis, MO

Abstract

A 66-year-old man with HIV and recurrent thromboembolism presented with new-onset ascites with an extensive diagnostic work-up that was unremarkable. He was diagnosed with non-cirrhotic portal hypertension after a liver biopsy revealed mild fibrosis and hepatic venography revealed an elevated hepatic venous pressure gradient. The etiology of portal hypertension was attributed to didanosine therapy, a rare but noted side effect.

Introduction

Portal hypertension is typically attributed to the presence of underlying cirrhosis, though, in rare cases, may result from alternate pathologies. This phenomenon, known as non-cirrhotic portal hypertension (NCPH) can arise from idiopathic portal hypertension, extrahepatic portal venous thrombosis, schistosomiasis, veno-occlusive disease, and congenital hepatic fibrosis.

Case Report

A 66-year-old white man with HIV, on treatment for 20 years, presented with several months of progressive abdominal distention and early satiety. He suffered from recurrent deep venous thromboembolism and pulmonary embolism for which an inferior vena cava (IVC) filter had been placed. His medications included tenofovir, didanosine, and nevirapine for several years, and chronic anticoagulation with coumadin. He had no significant alcohol use.

His examination showed a protuberant abdomen with a fluid wave, shifting dullness, and a palpable spleen. Laboratory values revealed normal electrolytes, renal function, hemoglobin, and white blood cell count. His platelet count was 110,000 U/mL. His hepatic panel revealed an alanine aminotransferase (ALT) 24 U/L, aspartate aminotransferase (AST) 43 U/L, bilirubin 0.4 mg/dL, alkaline phosphatase 157 U/L, total protein 5.9 g/dL, and albumin 3.3 g/dL. His international normalized ratio (INR) was 1.8 (on coumadin therapy). His CD4 count was 278 cells per mm3 and HIV viral load was undetectable.

A Doppler ultrasound and abdominal computed tomography (CT) revealed ascites, but was otherwise normal. A diagnostic paracentesis revealed a serum ascites–albumin gradient of 1.5 g/dL with a total protein of 2.7 g/dL. Chest
radiograph and echocardiogram were normal. A chronic liver disease work-up was negative, including hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, anti-hepatitis C virus antibody, antinuclear antibody, anti-mitochondrial antibody, anti-smooth muscle antibody, iron studies, α-1 antitrypsin phenotype, and ceruloplasmin. Stool examination did not show evidence of schistosomiasis. Acid-fast bacilli culture and smear of the peritoneal fluid and quantiferon-gold testing was negative.

A transjugular liver biopsy revealed a hepatic wedge pressure of 26 mm Hg, free hepatic vein pressure of 12 mm Hg, and mild perisinusoidal fibrosis without bridging fibrosis, confirming the diagnosis of NCPH (Figure 1).

Discussions

Didanosine is an antiretroviral agent frequently used as part of highly active antiretroviral therapy (HAART). NCPH is an increasingly seen complication associated with didanosine exposure, which has led the Food and Drug Administration to update the labeling of the drug. While the mechanism by which didanosine causes NCPH is not known, it may be caused by depletion of intracellular glutathione with subsequent death of sinusoidal endothelial cells. A potential genetic predisposition and causal effect of duration of didanosine therapy have been implicated in its pathogenesis. A large case-control study performed in the Netherlands has implicated tenofovir when issued concomitantly with didanosine to an increased risk of NCPH. Management involves cessation of the causative drug and treatment of portal hypertension-related sequelae.

Disclosures

Author contributions: M. Stotts wrote and edited the manuscript. P. Chisholm assisted with data collection, including images. D. Nurutdinova provided writing and editing assistance. H. Maddur wrote and edited the manuscript, and is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received: July 22, 2014; Accepted: December 3, 2014

References

1. Runyon BA, Montano AA, Akriavidis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117(3):215–20.
2. Schouten JN, Garcia-Pagan JC, Valia DC, Janssen HL. Idiopathic non-cirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.
3. Parikh ND, Martel-Laferriere V, Kushner T, et al. Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: A proposed diagnostic algorithm. J Infect Dis. 2014;209(5):734–738.
4. Schouten JN, Van der Ende ME, Koeter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther. 2012;36(9):875–885.
5. Chang HM, Tsai HC, Lee SS, et al. Noncirrhotic portal hypertension associated with didanosine: A case report and literature review. Japan J Infect Dis. 2012;65(1):61–5.
6. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: A new clinical condition? Prevalence, predictors and outcome. Antivir Ther. 2008;13(1):103–7.